Pharmacologic treatment of type 2 diabetes

Diabetes Care

Volumn 26, Issue 2, 2003, Pages 526-533

  Bloomgarden, Zachary T ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; DEOXYGLUCOSE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EXENDIN; G PROTEIN COUPLED RECEPTOR; GASTRIC INHIBITORY POLYPEPTIDE; GHRELIN; GLIMEPIRIDE; GLIPIZIDE; GROWTH HORMONE SECRETAGOGUE; METFORMIN; NATEGLINIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLACEBO; PRAVASTATIN; RAMIPRIL; REPAGLINIDE; SULFONYLUREA DERIVATIVE; TOPIRAMATE; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; EXENDIN 4; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLUCOSE TRANSPORTER; INSULIN; PEPTIDE; PEPTIDE FRAGMENT; PEPTIDE HORMONE; PEROXISOME PROLIFERATOR; PROTEIN PRECURSOR; THIAZOLE DERIVATIVE; VENOM;

BLOOD PRESSURE REGULATION; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; INSULIN RESPONSE; INSULIN SENSITIVITY; LIFESTYLE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; REVIEW; CONFERENCE PAPER; HUMAN; METABOLISM; SECRETION;

DIABETES MELLITUS, TYPE 2; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HUMANS; INSULIN; MONOSACCHARIDE TRANSPORT PROTEINS; OBESITY; PEPTIDE FRAGMENTS; PEPTIDE HORMONES; PEPTIDES; PEROXISOME PROLIFERATORS; PROTEIN PRECURSORS; RECEPTORS, CELL SURFACE; THIAZOLES; VENOMS;

EID: 0041308200     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.2.526     Document Type: Review

References (8)

1. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M: Acarbose for prevention of type 2 diabetes: the STOP-NIDDM randomised trial. Lancet 359:2072-2077, 2002
2. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, Azen SP: Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 51:2796-2803, 2002
3. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, Isles C, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, Shepherd J, Gaw A: Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103:357-362, 2001
4. Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BH, Zinman B: Ramipril and the development of diabetes. JAMA 286:1882-1885, 2001
5. Kahn BB, Cushman SW: Subcellular translocation of glucose transporters: role in insulin action and its perturbation in altered metabolic states. Diabetes Metab Rev 1:203-227, 1985
6. Wang Y, Okamoto M, Schmitz F, Hofmann K, Sudhof TC: Rim is a putative Rab3 effector in regulating synaptic-vesicle fusion. Nature 388:593-598, 1997
7. Fischer R, Wei Y, Anagli J, Berchtold MW. Calmodulin binds to and inhibits GTP binding of the ras-like GTPase Kir/Gem. J Biol Chem 271:25067-25070, 1996
8. Miki T, Liss B, Minami K, Shiuchi T, Saraya A, Kashima Y, Horiuchi M, Ashcroft F, Minokoshi Y, Roeper J, Seino S: ATP-sensitive K+ channels in the hypothalamus are essential for the maintenance of glucose homeostasis. Nat Neurosci 4:507-512, 2001